Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Bristol Myers Squibb (BMY) closed at $60.28 in the latest trading session, marking a +0.79% move from the prior day.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...

K reports of America’s largest pharmaceutical companies show that they continue to avoid paying much, if any, U.S. corporate income tax.

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

Treatment-experienced patients with moderate to severe atopic dermatitis attained higher efficacy rates on rocatinlimab ...

Garmin is celebrating World Sleep Day with a look at all the ways Garmin smartwatches can help users appreciate how a good night's sleep can enhance their well-being and performance. Insights from the ...